DEA Stretches Virtual Controlled Drug Prescriptions to 2026
Published Date: 12/31/2025
Rule
Summary
The DEA and HHS are extending special telemedicine rules that let doctors prescribe controlled medications without an in-person visit through December 31, 2026. This helps patients who need these meds get care safely from home. Doctors and patients can keep using telehealth for these prescriptions without extra costs or delays during this time.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Keep Telemedicine Prescriptions Open
You can continue to get prescriptions for Schedule II-V controlled medications by telemedicine without an in-person medical visit if the rule's conditions are met. The temporary extension covers telemedicine prescribing from May 12, 2023 through December 31, 2026 and the rule is effective January 1, 2026 through December 31, 2026. The agencies note that in 2024 about 7 million prescriptions (roughly 16 percent of 44.6 million) were issued without a prior in-person medical evaluation.
Estimated Patient Cost Savings
DEA and HHS estimate patient cost savings from this extension: $18.4 million in the first year and a net present value of $17.2 million at a 7% discount rate. The agencies say the extension creates cost savings to patients and prescribers by avoiding the need for some in-person care during the extension period through December 31, 2026.
Fewer Requirements Than Final Rules
The temporary rule imposes fewer requirements than two related final rules that also address telemedicine prescribing. Practitioners who are covered by one or both of the Two Final Rules may still use this temporary extension (through December 31, 2026) so long as they meet the temporary rule's conditions, which can reduce compliance burdens during the extension.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2025-05007 — Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans and others needing buprenorphine treatment can get care through telemedicine, making it easier and faster to access help. The government delayed these new rules to review feedback and make sure everything’s just right. This change means more people can get treatment from home without extra costs or trips to the doctor.
2025-02793 — Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting March 21, 2025, veterans and others needing buprenorphine treatment can get care through telemedicine more easily. The government is delaying new rules to make sure everything’s just right and wants your thoughts on the delay. This change helps veterans keep their treatment going without extra trips, saving time and hassle.
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13989 — Mark Allen, D.D.S.; Decision and Order
Mark Allen, D.D.S., lost his DEA registration because he no longer has permission to handle controlled substances in Oklahoma. He didn’t ask for a hearing, so the DEA canceled his registration by default. This means he can’t legally prescribe or manage controlled drugs anymore, effective immediately, impacting his dental practice and any related income.
2026-13992 — Timothy Genetta, D.O.; Decision and Order
Dr. Timothy Genetta from Ohio lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA canceled his registration by default. This means he must stop prescribing or handling these drugs immediately, with no money or timing benefits for him.
Previous / Next Documents
Previous: 2025-24113 — Cotton Board Rules and Regulations: Adjusting Supplemental Assessment on Imports (2025 Amendments)
Starting March 1, 2026, importers of cotton and cotton products will see a change in how their supplemental fees are calculated. The USDA is lowering the value assigned to imported cotton to match the fees paid on U.S.-grown cotton, keeping things fair. This update also refreshes the Import Assessment Table to reflect recent changes since 2024.
Next: 2025-24127 — Delegation of Authority to the Director of the Division of Investment Management
Starting December 31, 2025, the Director of the Division of Investment Management gets the power to approve or deny requests to keep certain investment info secret. This change helps the SEC work faster and saves resources by letting the Director handle these decisions directly. It mainly affects companies filing investment adviser info and speeds up how confidential info is managed.